Hepatocellular (HCC) surveillance guidelines for patients with chronic hepatitis B virus (HBV) infection are based on race-and age-specific estimates of HCC risk, derived from studies conducted in areas in which HBV is endemic.
C hronic hepatitis B virus (HBV) infection is a common condition with approximately 1.4 million infected persons in the United States. 1 Patients with HBV are at increased risk of developing cirrhosis and hepatocellular carcinoma (HCC). 2 The risk of HCC is the greatest in HBV patients of African or Asian origin. 3 In addition, age strongly is associated with HCC risk; the incidence of HCC is low before age 40, but then increases exponentially. 4 Given these data, HCC surveillance guidelines in the United States use cirrhosis, age, and race as the major criteria for HCC risk stratification in HBV. 3 Specifically, HCC surveillance is recommended for all patients with cirrhosis. In the absence of cirrhosis, HCC surveillance is recommended for Asian men older than age 40 and Asian women older than age 50.
The guidelines also suggest that surveillance should start at a younger age for African/North American blacks, without an exact specification of the age cut-off year.
Most of the knowledge about the risk of HCC in HBV is based on studies conducted in Southeast Asia and sub-Saharan Africa, where HBV infection is endemic and acquired at birth or early childhood. 5, 6 There are limited data on the risk of HCC in HBV-infected patients in the United States; most of whom primarily acquire HBV later in life compared with patients from HBV-endemic regions. Most studies from the United States reporting clinical outcomes of chronic HBV have either studied ethnic minorities (eg, Alaskan natives) or cohorts in whom the majority was of Asian origin and limited by a relatively small sample of patients with HCC. [7] [8] [9] [10] [11] [12] [13] Therefore, we conducted a retrospective cohort study of more than 8300 racially diverse US Veterans with chronic HBV and more than 7 years of follow-up evaluation to examine the effect of race and age on the risk of progression to HCC.
Methods

Data Source
We extracted data from the Veterans Administration (VA) Corporate Data Warehouse (CDW) housed on the VA Informatics and Computing Infrastructure to derive the study cohort and variables. 14 The CDW includes patient demographics, and outpatient clinic and inpatient utilization including diagnosis (International Classification of Diseases, 9th revision ) and procedure (Common Procedural Terminology) codes, laboratory data, pharmacy data, and vital status information including date of death.
Study Population
The study cohort included patients with chronic HBV, defined as a positive hepatitis B surface antigen (HBsAg) test followed by 1 or more positive HBsAg, HBe antigen (HBeAg), or HBV DNA test 6 months or more after the index HBsAg test 3, 4 between January 1, 2001, and December 31, 2013. We defined the date of first positive HBsAg as the index date for this analysis. We excluded patients who had a prevalent diagnosis of HCC defined as evidence of HCC any time before or within 365 days after the index date. We also excluded patients with less than 1 year of follow-up evaluation in the VA to minimize bias related to incomplete ascertainment of patients' HCC risk.
Study Exposure
We calculated the patient's age at the time of the index date. We identified and categorized race/ethnicity from 2 variables (race and ethnicity) in the data set into the following groups: whites (Caucasian race and those of Hispanic ethnicity irrespective of race); African Americans; Asians, Native Hawaiians, Pacific Islanders, American Indians, and Alaskan natives as API; and unknown/unreported race.
Study Outcomes
The primary outcome of the study was new cases (incident) of HCC that were first recorded 1 year after the index date. We used a 2-step process to identify patients with incident HCC. We first extracted patients in our cohort with 1 or more instances of an ICD-9 code for HCC (155.0) in the inpatient or outpatient files of the automated CDW data. Two individuals (S.M. and R.O.) then conducted a manual structured review of the electronic medical record to confirm the HCC diagnosis and determine the date of diagnosis for each case identified on the basis of the ICD-9 code. We used the American Association for the Study of Liver Diseases guidelines to confirm the HCC diagnosis, as previously described. 3 We defined the date of HCC diagnosis as the date of liver biopsy confirming the HCC diagnosis or, in the absence of histopathologic evidence, the date of the diagnostic imaging test (computed tomography or magnetic resonance imaging). The study follow-up evaluation ended at the time of HCC diagnosis, death, last visit recorded in the VA Medical Center, or December 31, 2014, whichever came first.
Potential Confounders
In addition to age and race, we included sex, baseline alanine aminotransferase (ALT) level, cirrhosis, diabetes, alcohol use, human immunodeficiency virus (HIV) co-infection, hepatitis C virus (HCV) co-infection, body mass index, receipt of antiviral treatment, baseline HBeAg, and HBV DNA levels.
We defined cirrhosis on the basis of ICD-9 codes (571.2, 571.5, and 571.6) or a FIBROSIS-4 value greater than 3.25 within 1 year before and after the index date. 15 We defined diabetes and alcohol abuse on the basis of corresponding ICD-9 diagnosis codes recorded anytime before the index date. We defined HCV co-infection by a positive HCV RNA, and HIV co-infection by a positive Western blot or HIV RNA or the presence of an ICD-9 code for HIV along with a CD4 assay. 16 We used the ALT, HBeAg, and HBV DNA tests performed within 1 year before or after the index date and recorded the value for each test that was closest to the index date. HBV DNA levels reported as picograms per milliliter or copies per milliliter were converted to international units per milliliter (1 pg/mL ¼ 270,000 copies/mL; 1 IU/mL ¼ 5 copies/mL). 17, 18 We defined antiviral treatment as any filled prescription for interferon and nucleos(t)ide analogs (lamivudine, telbivudine, adefovir, tenofovir, and entecavir) anytime during the study period.
Data Analysis
We calculated HCC incidence rates per 100 personyears (PY) for newly diagnosed cases of HCC overall, as well as stratified by racial groups (whites, African Americans, and API) and age (<40, 40-49, 50-59, and 60 y). We generated Kaplan-Meier curves to illustrate and compare the cumulative incidence rates of HCC among racial groups beginning 1 year after the index date until the end of the follow-up period. We then compared the risk for HCC between the racial and age groups using Cox proportional hazard regression analyses, adjusting for potential confounders. The proportional hazard assumption was tested and fulfilled in all models. Although we included all patients regardless of underlying severity of chronic HBV (CHB) in the primary analysis, we conducted subgroup analyses based on the presence or absence of active CHB (defined as a high ALT level in the absence of cirrhosis) to examine if the effect of race on HCC risk was different in the 2 subgroups.
Results
Our study cohort included 8329 patients with chronic HBV who were followed up for a mean of 7.1 years (SD, 3.4 y). Among the cohort, 12.5% were younger than 40 years old, 28.3% were 40 to 49 years old, 37.8% were 50 to 59 years old, and 21.4% were older than 60 years old. More than 71% of patients had an ALT value greater than 40 IU/mL and 30.5% had cirrhosis at the time of the HBV index date. Approximately 23.5% had diabetes, 28.5% abused alcohol, 11.2% had HCV co-infection, and 13.6% had HIV co-infection. A total of 18.0% had a positive HBeAg test and 29.6% had a negative HBeAg test; HBeAg was not tested in 51.4% of patients. Similarly, 23.5% of patients had a high HBV DNA level (2000 IU/mL), 20.6% had a low DNA level (<2000 IU/ mL), and 56.0% did not have any HBV DNA test within 1 year before or after the index date. A total of 45.7% received HBV antiviral treatment during the study period.
A total of 3498 (42.0%) patients were white, 3248 (39.0%) were African American, and 659 (7.9%) were API; race was unknown or unreported in 924 (11.1%) patients. Notably, African Americans were younger and were less likely to have cirrhosis or a high ALT level compared with whites (Table 1 ). However, they were more likely to have HIV co-infection and abuse alcohol, and less likely to receive antiviral treatment than whites. APIs were younger, less likely to have a high ALT level, cirrhosis, diabetes, HIV or HCV co-infection, history of alcohol abuse, or receive antiviral treatment than whites. The mean age at the time of the HCC diagnosis was 59.2 years (SD, 9.1 y) in African Americans, 61.2 years in whites (SD, 8 y), and 59.7 years in API (SD, 9.0 y).
Association Between Race and Risk of Incident Hepatocellular Carcinoma
After an overall follow-up period of 58,971.2 PY in 8329 patients, 303 (3.6%) patients developed HCC, for an incidence rate of 0.51 per 100 PY. The annual incidence rate for HCC was the highest in API (0.65 per 100 PY), followed by whites (0.57 per 100 PY), and African Americans (0.40 per 100 PY) ( Table 2 ). Figure 1 shows the overall cumulative incidence of HCC stratified by race (log-rank test P ¼ .01). The annual incidence of HCC was higher in males than in females. In 367 women followed up for a mean period of 6.9 years, 1 developed HCC for an annual incidence of 0.04 per 100 PY. The annual incidence increased after age 40 years (log-rank test P < .001) (Figure 2 ). The incidence rates of HCC were 0.13, 0.37, 0.60, and 0.90 per 100 PY in patients younger than age 40, ages 40 to 49, ages 50 to 59, and older than age 60 years, respectively. The annual incidence rate of HCC was 1.23 per 100 PY in patients with cirrhosis and 0.38 per 100 PY in those without cirrhosis at baseline.
We examined the association between race, age, and incident HCC after adjusting for several clinical and viral factors (Table 3) . African Americans had a lower risk of HCC than whites; however, this trend did not reach statistical significance (adjusted hazard ratio [HR], 0.77; 95% CI, 0.58-1.02). In contrast, the risk for HCC was significantly higher in APIs compared with whites (adjusted HR, 2.04; 95% CI, 1.31-3.17). HCC risk increased markedly with age; compared with patients younger than 40 years old the risk was approximately 2-, 3-, and 4-fold higher for patients between the ages of 40 and 49, 50 and 59, and those older than age 60 (adjusted HR, 1.97; 95% CI, 0.99-3.87; adjusted HR, 3.00; 95% CI, 1.55-5.81; and adjusted HR, 4.02; 95% CI, 2.03-7.94, respectively).
Several other factors also were associated with the risk of incident HCC. Women had a significantly lower risk than men (adjusted HR, 0.14; 95% CI, 0.02-0.98). Patients with cirrhosis (adjusted HR, 3.69; 95% CI, 2.82-4.83), those who received antiviral treatment (adjusted HR, 1.75; 95% CI, 1.33-2.29), and those with a history of alcohol abuse (adjusted HR, 1.37; 95% CI, 1.05-1.80) had a higher risk of HCC than their respective counterparts (Table 3) . We examined whether the risk of HCC was different in cirrhosis patients who were on antiviral treatment vs those who were not treated. Although cirrhosis patients on antiviral treatment had a lower risk of progression to HCC than untreated patients, this difference did not reach statistical significance (HR, 0.71; 95% CI, 0.43-1.17). The race effect did not change in this stratified analysis (by antiviral treatment) or when we stratified the models by body mass index and alcohol abuse (results not shown). Table 4 shows the results of the prespecified subgroup analyses. The effect of race was consistent across all subgroup analyses. Specifically, there was no difference in the risk of HCC in African Americans vs whites, in older or younger patients, in patients with and without cirrhosis, and in patients with or without active CHB or HBV mono-infection. APIs had a higher risk of HCC than whites in all subgroups. Baseline cirrhosis was associated with a high risk of HCC in all racial groups (1.17%, 0.94%, and 3.40% in whites, African Americans, and APIs, respectively). The annual HCC incidence was low in all patients younger than age 40, particularly among African Americans (0.03 per 100 PY). The annual incidence of HCC was higher than 0.2 per 100 PY in patients older than 40 years, regardless of race. This high risk was limited solely to patients with a high ALT level at baseline (0.40, 0.31, and 0.54 per 100 PY in whites, African Americans, and APIs, respectively). The annual risk of HCC was low in noncirrhotic patients older than age 40 years but with a normal ALT level at baseline.
Discussion
We studied a large racially diverse cohort of US patients with chronic HBV and observed that the risk of HCC differed by race, with the highest incidence among APIs followed by whites and African Americans. The risk of HCC markedly increased with age older than 40 years, irrespective of race. The risk of HCC was higher in men and among patients with cirrhosis.
Studies of Western patients with chronic HBV have reported variable incidence rates of HCC. A study including 317 Canadians with chronic HBV reported no cases of HCC after 16 years of follow-up evaluation. 9 However, the majority of the study population had normal liver enzyme levels, were asymptomatic carriers, and fewer than 2% had cirrhosis. McMahon et al 19 reported an HCC incidence of 0.26% per year in a study of 1400 chronic HBV Alaskan natives. Another study of a heterogeneous urban cohort from Canada observed an annual incidence of HCC of 0.46%. 7 A multicenter study from the United States reported an annual incidence of 0.42%, although more than 50% of the cohort was API in origin. 13 In this large and multiracial cohort of patients with HBV, we found that HCC developed at an annual incidence of 0.51% overall. The incidence varied based on the presence or absence of cirrhosis; it was as high as 3.4% in API patients with diagnosed cirrhosis and as low as 0.23% in African Americans without cirrhosis, respectively.
Our results have important implications for HCC surveillance in HBV in the United States. The current American Association for the Study of Liver Disease guidelines recommend HCC surveillance among HBV patients based on the HCC incidence rate thresholds of 0.2% or greater per year among those without cirrhosis, and between 0.2% and 1.5% per year among patients with underlying cirrhosis. 3, 4, 20, 21 We found that the annual risk of HCC was high in all patients with cirrhosis, ranging from 0.94% in African Americans to as high as 3.4% in APIs. These data provide support to the guidelines recommending HCC surveillance in all HBV-infected individuals with underlying cirrhosis.
For patients without cirrhosis, the guidelines rely on race and age criteria. These recommendations are based mostly on data from non-US cohorts. In particular, surveillance is recommended for Asians older than 40 years of age. Our study confirmed the age effect observed in the studies conducted in East Asia; the risk of HCC increased with age and the inflection point for markedly increased risk of HCC was among those older than 40 years. However, we also found that HCC risk was high (annual incidence greater than the proposed 0.2% threshold) among chronically infected patients older than 40 years without cirrhosis but with a high ALT level, irrespective of patients' race. We recognize that a high ALT level may be related to other (co-existing) liver diseases such as nonalcoholic fatty liver disease. Regardless of the main underlying cause for increased ALT level, these US-based data suggest that male HBV patients older than age 40 years without cirrhosis but with a high ALT level (>40 IU/mL) at the time of HBV diagnosis might benefit from HCC surveillance. Future studies are needed to determine if the risk of HCC diminishes with a decrease in ALT level (with or without treatment).
Two previous studies showed that African blacks with HBV might develop HCC at an age younger than 40 years. The first study, conducted at a single medical center in South Africa in 1977, included 328 Mozambican and 122 black South African men with HCC from HBV. The mean age at HCC diagnosis was 33 and 40 years, respectively. 22 The second study, conducted at the same facility and published in 1988, compared 173 South African blacks who developed HCC at a younger age (all <30 y) with 218 blacks who developed HCC at an older age (>50 y). Younger HCC patients were significantly more likely to have positive HBV serum markers than Figure 2 . Cumulative incidence of HCC among HBV cohort stratified by age (log-rank test, P < .001). older HCC patients. 23 Based on these data, current guidelines favor starting surveillance at a much younger age (without age specification) for Africans/Africans Americans. We found an extremely low risk of HCC in all individuals younger than age 40 years; including African American patients (annual incidence, 0.03%). In our study, the mean age at HCC development in African American patients was 59.2 years (SD, 9.1 y). Furthermore, irrespective of age, the risk of HCC among African Americans with chronic HBV was not statistically significantly different from the risk in whites. This might be explained by the fact that the majority of African American patients in our study (similar to whites) likely acquired HBV later in life compared with patients included in earlier reports from sub-Saharan Africa where HBV is acquired at birth or in early childhood. Our data show that in the United States, the risk of HCC in African Americans with HBV, particularly in those younger than age 40 years, might indeed be lower than the risk documented in previous reports; these patients may not need surveillance at an earlier age compared with patients of other racial groups.
Our study included a large and diverse cohort of patients with documented chronic HBV infection seen in routine care across VA hospitals in the United States, and followed up for more than 7 years. The findings of our study represent outcomes in real-world scenarios rather than in restrictive clinical trials. We used chart-confirmed cases of HCC instead of relying solely on previously collected administrative data for HCC. Approximately 45% of our patients were on antiviral treatment and therefore the risk of HCC and the effect of age and race on these estimates may be applicable to the broader group of US patients on HBV treatment. The study cohort included 367 women who were followed up, 1 woman developed HCC during the mean follow-up period of 6.9 years therefore we cannot make strong inferences about HCC risk in HBV-infected women from our study. Our study results may not be generalizable to other populations, particularly to women with HBV, blacks from Africa, and Asian Americans. However, our study included a large group of white and African American patients with HBV in the United States (<8% of our cohort comprised APIs) and thus extends our findings to a broader US community-based population. Several unmeasured patient characteristics also could have affected our results. Specifically, although we accounted for HBV antiviral treatment in our regression models, we did not fully examine the effectiveness of antiviral treatment in suppressing HBV in this study. Our finding of higher risk of HCC in treated vs untreated patients might be related to the types of patients who received antiviral treatment and should not be construed as evidence against potential benefits of antiviral treatment. Future studies will focus on treatment effectiveness in this patient population. The main focus of the study was the effect of race and age and we conducted several stratified analyses to confirm our findings. We also might have underestimated the extent of alcohol use in this study. We did not have information on some factors known to influence the risk of HCC in HBV such as family history of HCC, co-infection with delta virus, HBV genotype, or co-existing liver diseases such as nonalcoholic fatty liver disease. More than half of the patients in this study did not receive a test for HBeAg or HBV DNA within a year of their first positive HBsAg test. These data suggest quality gaps in a high-risk population and may serve as targets for future quality-improvement initiatives.
In summary, race and age were associated significantly with the risk of HCC in this cohort of predominantly male veterans with chronic HBV infection. The risk of HCC was highest among APIs, followed by whites, and lowest among African Americans with chronic HBV. This race-specific association was independent of age, and persisted after adjusting for a range of clinical factors. HCC risk was very low in patients younger than age 40 in all racial groups, particularly among African Americans. Our data show that patients with HBV cirrhosis might benefit from HCC surveillance. Even in the absence of cirrhosis, the risk of HCC was high enough in men who were older than age 40 and had increased ALT levels to warrant consideration of surveillance. Our results should prompt further studies to estimate the risk HCC among US patients with HBV to have more robust surveillance recommendations.
